Document is current
Any future updates will be listed below
-
Authors
Palmer, Andrew https://orcid.org/0009-0008-5239-0676
Rauscher, Garth
Schoen, Alexa
Burkart, Madelyn
Dunton, Ashley
Au, Cherry
Dave, Ami
Nassar, Ahmad
Zhu, Shaoshi
O’Hara, Alexander
Africawala, Nusrat
Erra, Amani
Solipuram, Vinod
Abraham, Ivy
Tsai, Stephanie B.
Zia, Maryam
Larson, Melissa L.
Rondelli, Damiano
Altman, Jessica K.
Stock, Wendy
Khan, Irum
Odenike, Olatoyosi
Patel, Anand Ashwin https://orcid.org/0000-0002-0296-8686
-
Funding
Funding for this research was provided by:
Calvin Fentress Research Fellowship
- License Information
-
More Information
Article History
Received: 18 June 2025
Revised: 5 August 2025
Accepted: 5 September 2025
First Online: 6 October 2025
Competing interests
: Tsai: Jazz, Sanofi: Honoraria; Bristol Myers Squibb: Membership on an entity’s Board of Directors or advisory committees. Rondelli: Vertex Pharmaceuticals: Honoraria. Altman: AbbVie, Aptitude Health, Astellas Pharma, BioSight, Bluebird Bio, Curio, Daiichi Sankyo, Dark Blue Therapeutics, Gilead, Kura Oncology, Kymera, Stemline Therapeutics, Treadwell Therapeutics, Rigel, Syros: Honoraria; AbbVie, Agios, ALX Oncology, Amgen, Amphivena, Aprea AB, Aptose Biosciences, Astellas Pharma, BioSight, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cyclacel, Fujifilm, Immunogen, Kartos Therapeutics, Kura Oncology, Loxo, Pfizer: Research Funding. Stock: Kura: Research Funding; Adaptive: Consultancy, Honoraria; Kura, Servier, Newave, Adaptive, Jazz, Asofarma: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees. Odenike: AbbVie (Inst); Agios (Inst); Aprea AB (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CTI BioPharma Corp (Inst); Daiichi Sankyo (Inst); Incyte (Inst); Janssen Oncology (Inst); Kartos Therapeutics (Ins: Research Funding; AbbVie; Blueprint Medicines; BMS; Bristol-Myers Squibb/Celgene (Inst); Celgene; CTI; Impact Biomedicines; Kymera; Novartis; SERVIER; Taiho Pharmaceutical; Treadwell Therapeutics: Honoraria. Patel: honoraria from AbbVie, Astellas, Amgen, Jazz, Sobi, Syndax; research funding (institutional) from Pfizer, Incyte, Servier, Sumitomo.
: The study was approved by the institutional review board (IRB) and ethical committee clearance was obtained (IRB23-0006). All clinical investigations were conducted according to the principles of the Declaration of Helsinki. Regarding informed consent, a waiver of consent was granted by the IRB as part of protocol approval due to this being a retrospective study that would be infeasible to carry out without a waiver of consent.
